Objectives: Examine hemodynamic and clinical correlates of use of an intra-aortic balloon pump catheter in a single center.
| M E TH ODS

| Patient characteristics
All patients who received IABC with a 50cc balloon for at least 1 hour were included in this study. Exclusion criteria were exchange of a 40cc for a 50cc IAB, lack of a Swan-Ganz catheter at the time of IABC placement and follow-up. Patients receiving a second 50cc IAB as a catheter exchange were not double counted. Variables collected included: Maquet provided research funding for the conduct of the study.
The study protocol was reviewed and approved by the hospital Institutional Review Board.
| Definitions
All definitions were prespecified and agreed upon prior to chart reviews. The group was divided based on the arithmetic difference (delta) between the cardiac output at time points A and B. Patients with any increase in cardiac output between baseline and the first measurement of cardiac output were counted in the "responder" group and those whose cardiac output did not change or declined were counted as "nonresponders."
| R E SU LTS
Seventy-six patients had a right heart catheter placed for hemodynamic assessment and were treated with IABC therapy. Seventy-four patients had data on inotrope and vasoconstrictor medications available. The baseline characteristics are in Table 1 . Seventy-six patients had paired measurements of cardiac output. Sixty patients had a higher cardiac output with IABC treatment (responder group) and 16 did not (nonresponders). In the 60 patients in the responder group, cardiac output and index significantly increased from baseline 3.6 6 1.3 L/min to 5.2 6 1.8 L/min, and 1.8 6 0.5 L/min/m 2 to 2.6 6 0.8 L/min/m 2 , respectively, following IABC placement (P <0.0001 for both comparisons). In the 16 patients in the nonresponder group, cardiac output and index significantly decreased from baseline 4.4 6 0.9 L/min to 3. follow-up CPI. In addition, the same variability is seen for patients bridged (transplant or VAD) and those who were not bridged.
| Outcome of IAB support
In 37 patients (49% of the total), the balloon pump served as a "bridge"
to a higher level of support. Ten patients waited for orthotopic heart Table 2 shows the comparison of patients based on responder or nonresponder status. Responders were significantly younger but no different in weight, height, gender, blood pressure, heart rate, or left ventricular ejection fraction. Greater than 70% of patients in both groups were on inotropic therapy prior to IABC placement. A small but significant minority were on intravenous vasoconstrictor treatment.
| Hemodynamic and clinical correlation to responder status
Norepinephrine was uncommonly utilized (3 patients) and none of 
| Laboratory values
We examined multiple lab values and none correlated with response to IAB therapy. These variables included hemoglobin/hematocrit, serum creatinine, serum liver function tests including AST, ALT, alkaline phosphatase, and total bilirubin. Indices of anticoagulation such as prothrombin time and partial thromboplastin time did not differ significantly between groups either. Lactate levels were not routinely checked.
| Survival analyses
In this study, data was only collected during the index hospitalization but not following discharge. The overall survival was 96% at 10 days Next, we looked at survival in responders versus nonresponders.
There was no difference in survival between groups over 90 days The indication for IAB placement was divided into cardiogenic shock and noncardiogenic shock. Eighteen patients had an IAB placed for reasons other than cardiogenic shock and only one died. This is illustrated in Figure 5 . The trend was for worse survival in the cardiogenic shock group which is not particularly surprising (P 5 0.07). Given the disparity of responses, this may explain the previous impression that the average increase in cardiac output with IABC therapy is 0.5 L/min [2, 3] . The mean change is cardiac output for all 76 patients in this study was 1.1 6 1.4 L/min. The standard deviation is quite wide, consistent with the disparate populations of responders and nonresponders. It is also noteworthy that this study did not The other major finding of this study is that simply improving the cardiac output does not correlate with ultimate outcome. One of the difficulties with studying cardiogenic shock is that it is a complex syndrome and reduced cardiac output is just one of the components of the syndrome. For this reason, devices such as the Tandem Heart left atrial to femoral artery bypass pump and the Impella (2.5 or CP) have not convincingly improved clinical outcomes in cardiogenic shock either above and beyond IABC [7] [8] [9] [10] . This dissociation between hemodynamic improvement and survival challenges our understanding of cardiogenic shock.
If cardiogenic shock survival was solely related to the restoration of adequate cardiac output, then the newer generations of increasingly capable mechanical circulatory support pumps would have resulted in incremental improvements in outcomes. Indeed, even the use of venoarterial extracorporeal membrane oxygenation (compact form of cardiopulmonary bypass) has not significantly changed the approximately 40-50%
short term mortality of this devastating condition [11] [12] [13] .
It has long been recognized that cardiogenic shock starts with an insult and then proceeds in a cascading pathway which may be difficult to interrupt [14] . The importance of nitric oxide overproduction in cases of inappropriate vasodilatation was recognized and led to the use of a nitric oxide synthase inhibitor in 3 trials of cardiogenic shock with a patent infarct related artery. Despite promising early results [15] , subsequent randomized controlled studies failed to demonstrate a mortality benefit [16, 17] . A number of cytokines are involved in the cascade of inflammation that accompanies severe cardiogenic shock, and it is likely that there are shared characteristics between cardiogenic and septic shock [18] [19] [20] [21] [22] [23] [24] .
This study along with the prior work on the 50 cc IAB [1] for responder patients is larger than previously quoted [25] . This work is complementary to other studies in different settings such as IAB SHOCK-2 which failed to demonstrate a survival advantage with IAB therapy (using a 40 cc IAB platform and a postinfarct setting) [10, 26] .
Another useful role for the IAB is as a bridge to decision. Given the relatively low cost and ease of insertion, IABC placement is an ideal initial treatment strategy, particularly if CPI is low ( 0.3) since the current study suggests that an improvement in cardiac output can be expected.
In addition, in cases where the ultimate treatment is unclear (unconscious patients, or elderly patients where a large caliber device may be difficult to place, or patients who may not be a candidate for escalation to more advanced therapies), the IAB represents a good first strategy.
| LI M I TA TI ON S
This is a retrospective review of data and therefore not all patients had hemodynamic data which was complete. For this reason, we only have mortality data during the hospitalization and had to censor observations at the time of discharge. This is in comparison to other prospective device studies which have uniform determination of outcomes at 1 month and beyond. We did not have lactate levels as an objective indicator of hypoperfusion and resolution.
| CON CL U S I ONS
The 50 cc IABC is associated with a significant improvement in cardiac output in selected patients. Predictors of significant improvement in cardiac output include low cardiac output and cardiac power index, with the mean improvement of 1.6 L/min. On the other hand, patients with relatively normal cardiac output (above 2 L/min) may experience 
